TerrAscend Corp.

TSX:TSND.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$0.52 -1.61%

-$0.02 today

Market cap
$193.65M
Beta
2.04
P/E (TTM)
-2.5
EPS (TTM)
-$0.26
52W Low $0.33High $2.00

Volume 0.26M

Average 0.31M

TSND.TO Net Income

Bottom-line profit, the starting point for calculating cash from operations.

TerrAscend Corp.TSX: TSND.TO

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income declines year over year

Q1 FY2026 net income of $6.83M (cash outflow) fell 44.3% year over year, ahead of the -71.2% change in trailing-twelve-month net income. Sequentially, it rose 314.1% from the prior quarter.

Context

  • Net income amounted to 9.2% of revenue in FY2025, down 14.5 pp from a year earlier.
  • Net income increased in 1 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 3 analysts of -$20.37M (-16.8%) for the fiscal year ending Dec 2026, a step up from the -66.3% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$6.83M+314.1% QoQ
Last fiscal yearDec 2025
-$24.49M-66.3% YoY
LTMMar 2026
-$20.19M-71.2% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-44.3%+71.4%+115.7 pp
1 year-66.3%-16.8%+49.5 pp
3-year CAGR—-17.9%—
5-year CAGR-18.1%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(24.49M) USD
Year-over-year change
+66.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How TSND.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -71.2% is the 8th highest of 10, against a peer median of -42.7%.
  • Net income amounts to 7.7% of revenue for TSND.TO, versus a peer median of 17.9%.
TSND.TO Competitors
Net Income for TSND.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$263.55M CAD-56.4%-28.6%84.8%
ACB.TOAurora Cannabis Inc.LTM Mar 2026CA$50.24M CAD-418.7%-39.5%15.8%
EPRX.TOEupraxia Pharmaceuticals Inc.LTM Mar 2026$42.94M USD+85.5%+18.4%—
XLY.TOAuxly Cannabis Group Inc.LTM Mar 2026CA$33.21M CAD+52.5%—20.9%
DR.TOMedical Facilities CorporationLTM Mar 2026$33.14M USD-68.8%+19.7%10.9%
CPH.TOCipher Pharmaceuticals Inc.LTM Mar 2026$31.07M USD+236.1%+0.9%61.0%
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026CA$25.21M CAD-249.3%—9.2%
TSND.TOTerrAscend Corp.LTM Mar 2026$20.19M USD-71.2%—7.7%
HLS.TOHLS Therapeutics Inc.LTM Mar 2026$10.31M USD-42.7%-19.2%18.5%
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 2026$8.81M USD-39.0%-25.7%17.2%
Peer median (excluding TSND.TO) —-42.7%-19.2%17.9%

Competitors are the stored peer set for TSND.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(21.82M)22.61M(27.63M)(72.67M)(24.49M)
Depreciation & Amortization13.63M23.87M30.64M22.99M17.51M
Deferred Income Tax(1.81M)(46.02M)(18.92M)(8.75M)(532K)
Stock-Based Compensation14.93M12.18M7.71M9.71M5.01M
Change in Working Capital(45.17M)37.81K35.67M28.84M23.24M
Accounts Receivables(4.02M)3.73M(12.5M)(2.95M)1.67M
Inventory(23.19M)881.27K(7M)4.17M6.05M
Accounts Payables3.53M(15.78M)869.2K(5.29M)(4.59M)
Other Working Capital(21.49M)11.2M52.07M32.91M20.11M
Other Non-Cash Items(4.62K)(38.8M)(2.42K)57.84M1.34M
Operating Cash Flow(38.43M)(33.38M)27.47M37.95M22.07M
Capital Expenditures(50.39M)(54.61M)(9.43M)(10.55M)(8.76M)
Acquisitions (Net)(53.55M)19.77M(16.79M)(250K)(8.68M)
Purchases of Investments(62.65M)0000
Sales of Investments00000
Other Investing Activities34.17M7.27M5.44M(2.64M)3.16M
Investing Cash Flow(132.42M)(27.58M)(16.22M)(12.25M)(15.03M)
Debt Repayment(3.67M)54.4K(27.76M)(17.18M)8.36M
Common Stock Issued200.83M23.62M20.82M00
Common Stock Repurchased000(215K)(417.18K)
Dividends Paid00000
Other Financing Activities(14.96M)(19.95M)(5.56M)(7.32M)(3.69M)
Financing Cash Flow182.2M3.72M(12.5M)(24.72M)4.26M
Effect of Forex Changes2.45M(2.9M)(168K)653K(2.11M)
Net Change in Cash20.42M(52.88M)(1.42M)1.64M9.19M
Free Cash Flow(88.82M)(88M)18.04M27.4M13.31M

TerrAscend Corp.

TSX:TSND.TO

Intrinsic Alpha fair value

Locked

Current Price

$0.52

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.